Purpose Treatment of patellar tendinopathy/jumper's knee with ultrasound-guided sclerosing injections or ultrasound-guided arthroscopic shaving has shown good clinical short-term results. Former studies indicate that the tendon thickness and structure stays unaffected after successful treatment. The aim of this study was to evaluate the sonographic findings and clinical outcome 3-5 years after treatment of patellar tendinopathy with ultrasound-guided sclerosing injections or arthroscopic shaving. Methods Fifty-seven patellar tendons (43 patients) with chronic patellar tendinopathy were evaluated, with ultrasound, colour Doppler (CD) and visual analogue scale (VAS) for pain and satisfaction with treatment, 3-5 years after treatment. Functional status was evaluated with a single question-''Back in full loading activity?'' yes or no. Results At endpoint (mean 46 months), there was a significant decrease in anteroposterior thickness of the proximal patellar tendon in patients treated with ultrasoundguided arthroscopic shaving but not after sclerosing injections. Tendon structure had improved, and CD local blood flow had diminished significantly in both groups.
Introduction
The aetiology and pathogenesis, as well as the healing process and recovery after treatment, of patellar tendinopathy/jumper's knee have not yet been completely clarified. Studies using grey-scale ultrasound (US) and power or colour Doppler (PD/CD) have shown hypoechogenic changes in the tendon structure and regions with high local blood flow (neovascularisation) inside and outside the dorsal side of the painful area in the tendon [1, 14, 23] . Additional immunohistochemical analyses of tendon biopsies from such regions have shown nerves in close relation to blood vessels [7, 10] . Altogether, these findings have challenged us to invent and scientifically evaluate new treatments such as US/CD-guided sclerosing injections (Polidocanol Ò ) [12, 22] and US/CD-guided arthroscopic shaving, targeting the regions with high blood flow outside the dorsal side of the patellar tendon [27, 29] . Both these treatments use US and CD as tools for diagnostics, for guidance of the intervention and for objective evaluation of the tendon.
Few studies have used US and CD to evaluate the tendon recovery after different treatment methods. In addition, the conclusions in some studies are contradictive concerning whether the structure and thickness improves after treatment of a tendinotic chronic painful tendon [3, 19] . Yet, most of these results are based on relatively short-term follow-ups (1-1.5 years). A recent study has shown that patients treated with arthroscopic shaving had a faster return to full activity, less pain and were more satisfied with the outcome 1 year after treatment, than patients treated with sclerosing injections [28] . This study attends medium-term follow-up results from these new methods regarding treatment of patellar tendinopathy. To the best of our knowledge, a medium-term follow-up of the specific surgical method described in this study has not been done before.
The aim and primary outcome of this study was to compare the US and CD findings between the two treatment methods. Secondary, we wanted to evaluate pain during sport activity (VAS) as well as satisfaction with treatment results, before and after treatment with US/CDguided sclerosing injections and US/CD-guided arthroscopic shaving, in a medium-term follow-up. The hypothesis was that a chronic painful tendinotic patellar tendon treated with US/CD-guided arthroscopic surgery, including shaving outside the dorsal side of the tendon, would sonographically show signs of a better recovery than a tendon treated with US/CD-guided sclerosing Polidocanol Ò injections (sclerosing injections outside the tendon aiming at the entrance of the transversal vessels entering the painful tendinotic part of the tendon from the dorsal side).
Materials and methods
Patients approached in this study were 45 former participants in a prospective randomised trial [28] -evaluating treatment with US/CD-guided sclerosing injections and US/CD-guided arthroscopic shaving-and an additional nine patients from a previous pilot study-evaluating the US/CD-guided arthroscopic shaving method-for patellar tendinopathy/jumper's knee [29] . A total of 43 patients (41 men/2 women) with 57 treated tendons chose to participate in this follow-up study. Patients were primarily referred to the clinic, with the diagnosis patellar tendinopathy/jumper's knee, and they were all practicing recreational or medium-to high-level competitive sports. All patients had chronic (symptoms more than 3 months) [16] proximal patellar tendon pain during activity and no acute onset of symptoms. All were diagnosed with US/CD, and they all presented typical tendinotic changes and increased blood flow in the affected region of the tendon (dorsally at the apex of patella). Our material consists mainly of men, and they are consecutive patients from the Stockholm region. We believe that the patient material is representative for the situation in our region [18, 31] .
The follow-up was carried out from May 2010 to August 2011. Patient characteristics are given in Table 1 and  patient activity in Table 2 .
Two different treatments had been used, US/CD-guided sclerosing injections [6, 13, 22] (Polidocanol Ò 10 mg/ml, Group A represents patients treated with sclerosing injections and group B patients treated with arthroscopic shaving. Proportion of males/females is presented within brackets maximum 2 ml per treatment) and US/CD-guided arthroscopic shaving [27] . After treatment, the recommendations for weight bearing and activity level were the same in both groups [28] . During the first 14 days after treatment, only normal activity of daily living, such as walking and light biking, was recommended. After 2 weeks, no set time frame preceding full tendon loading activity was obligated. The surgical group was recommended to respect intraarticular swelling. Patients treated with sclerosing injections had a follow-up 6-8 weeks after each treatment.
Another injection was given if the patient reported remaining sharp tendon pain during activity, together with US and CD showing remaining high blood flow in the region of interest [21] . Thirteen tendons treated with sclerosing injections without satisfying results after a third injection treatment period [2, 30] were considered as failures, and these patients were offered surgery and were therefore not included in this study. None of the patients included in this study had received any other type of treatment between the short-and medium-term follow-up. The diagnosis was confirmed at baseline with US and CD, showing a thickening of the proximal tendon, structural tendon changes and high blood flow inside and outside the dorsal side of the proximal patellar tendon. All tendons were examined with high-resolution grey-scale US and CD using a WSX 13-5 linear multifrequency probe (Siemens-Acuson Antares Sonoline), at a grey-scale frequency of 11.4 MHz and a colour Doppler frequency of 8.9 MHz. The same equipment was used for all examinations, and the same experienced sonographer performed all US and CD evaluations at baseline, at short-term follow-up and at endpoint (medium-term follow-up). Intra-observer reliability for evaluation of tendon structure and neovascularisation (localised high blood flow) had been tested, as well as reproducibility for measures of thickness with the following results: coefficient of variation (CV) for measures of thickness was 1.6 %, and intra-class correlation coefficient (ICC) was 0.99. Overall agreement and kappa coefficient (Oa/k) for evaluation of tendon structure was 0.90/0.78 and for neovascularisation (localised high blood flow) 0.94/0.85. The test-retest reliability had been evaluated by examining three patients (six tendons) ten times each, during a period of approximately 3 weeks. The CV was estimated to be 5.3 %, including the biological variation, and ICC was estimated to 0.87. Ultrasound investigations were performed according to a routine protocol for investigation of the patellar tendon. Patients were in a supine position with knees in extension and quadriceps muscles relaxed. US and CD registrations were taken in both longitudinal and transversal plane at the whole length of the patellar tendon. Tendon thickness-anteroposterior (AP) distance-was measured in the longitudinal plane at the most proximal part of the tendon in the centre of the tendinotic region, representing the widest part of the tendon, as shown in Fig. 1 . Tendon structure and neovascularisation (local high blood flow) were evaluated with the same criteria used at baseline and at short-term follow-up, according to a modified Ö hberg score [21] . Instead of the original 5-grade scale (0-4), we used a 4-grade scale (0-3) when evaluating the amount of neovascularisation inside the tendon in this study. In addition, we also used a 4-grade scale when evaluating the tendon structure. The modified Ö hberg score, used in this study, also describes the spreading and direction of the visible blood flow (Fig. 2) .
Tendon structure; 0-normal structure (homogenous echogenicity), 1-light structural changes (discrete hypoechogenic areas), 2-moderate structural changes (some well-defined hypoechogenic areas), 3-severe structural changes (extended hypoechogenic areas).
Neovascularisation (high blood flow); 0-no visible vessels, 1-mild neovascularisation (solitary transversal vessels in the proximal/ventral part), 2-moderate neovascularisation (moderate quantity, mostly transversal in the proximal part), 3-severe neovascularisation (several, mostly horizontal, vessels spread in the whole depth and more distally in the tendon) (Fig. 2 ).
All patients scored the level of patellar tendon pain during their specific sport or recreational activity, and at rest, on a 100-mm-long visual analogue scale (VAS), the worst experienced pain during the last 2 weeks was requested to be scored at all times. No pain was recorded as 0 and intolerable pain as 100. Self-reported satisfaction with the result of treatment was also scored on a 100-mmlong VAS. The percentage of satisfaction was scored from 0 to 100, where 100 per cent equals full satisfaction [9, 24] . All scores, at endpoint, were compared to the corresponding scores at baseline (before treatment) and at shortterm follow-up (mean 12 months). At both short-term follow-up and at endpoint, patients were asked to answer to the question whether they considered themselves to be back in full activity-i.e. the same level as before onset of symptoms-with yes or no. Primary outcome was sonographically evaluated differences in AP thickness, tendon structure and the amount of local blood flow (neovascularisation), between baseline (before treatment) and endpoint (mean 46 months after treatment).
The secondary outcome was the medium-term clinical effect of the treatment evaluated with VAS scores (0-1.00) for the level of patellar tendon pain at rest and during their specific sport or recreational activity and for patient satisfaction regarding the results of the treatment.
All subjects were presented oral as well as written information and were asked to sign a written consent. Power analysis showed that 16 tendons in each group would be required to demonstrate a significant difference in mean AP thickness between the two groups. Concerning Ö hberg score for neovascularisation power analysis resulted in a sample size of 11 tendons in each group. Significance level was set to 0.05 and power to 80 %.
Since we also wanted to evaluate the clinical outcome, we chose to include all patients from the short-term followup of a comparative study between US/CD-guided sclerosing injections and US/CD-guided arthroscopic shaving [28] . That study included 26 patients in each group which was six patients more in each group than the power calculation required for significant differences in VAS. In addition, we also included all 15 patients from a pilot study evaluating the US/CD-guided arthroscopic procedure [29] .
Results
The mean AP thickness of the proximal patellar tendon had decreased significantly from baseline to the final follow-up (endpoint) in the group treated with US/CD-guided arthroscopic shaving, but not in the group treated with US/ CD-guided sclerosing injections. There was initially a significant increase in proximal patellar tendon thickness in the US/CD-guided sclerosing injection group. However, at endpoint, the tendon thickness was similar as before treatment in this group. All results are shown in Tables 3  and 4 and in Fig. 3 .
The tendon structure was significantly less abnormal, and there was significantly less neovascularisation (high local blood flow) at the short-term follow-up compared to baseline, in both treatment groups. There was no further Fig. 2 Showing the amount of neovascularization (modified Ö hberg score): 0 = no visible vessels, 1 = mild neovascularization, 2 = fair neovascularization, 3 = severe neovascularization significant improvement at endpoint for the group treated with US/CD-guided arthroscopic shaving. A sonographically more normal tendon structure was seen earlier in the group treated with US/CD-guided arthroscopic shaving. At final follow-up (endpoint), there was a significantly decreased VAS for pain during activity in both groups and no significant difference in VAS between the groups. Furthermore, 74 % of the patients in the sclerosing injection group and 80 % of the patients in the arthroscopic shaving group scored C80 % in VAS for satisfaction with treatment result. A significant, correlation, both at followup and at endpoint, between low local blood flow and high patient satisfaction was found (follow-up -0.45 p \ 0.01; endpoint -0.56 p \ 0.001). At short-term follow-up, a correlation was found between large tendon thickness and high VAS pain at rest (0.66 p \ 0.01) in the arthroscopic shaving group. When including the whole material (US/CD findings and VAS pain during activity), regardless of time, a significant correlation was found between the amount of high local blood flow (neovascularisation) and VAS pain during activity (0.63 p \ 0.0001) as well as between the level of structural changes and the VAS pain during activity (0.52 p \ 0.0001).
At endpoint of this study, 11 patients (11 tendons) were missing in the arthroscopic shaving group and two patients (two tendons) in the sclerosing group. One patient (two tendons, one in each group) declined participation. For the remaining eleven tendons, only some information was reported, and no US and CD examination was able to be performed. Nine of the missing patients, living far outside the county of Stockholm, reported the distance as a reason not to participate in this final follow-up study. At endpoint, three of the missing patients (three tendons) treated with US/CD-guided arthroscopic shaving reported VAS for pain at rest and activity to be 0, and 100 % satisfaction with the result of the treatment. Ten patients (ten tendons) in the surgical group and one patient in the sclerosing group reported to be back in full activity. At short-term follow-up (mean 12 months), all of the, at endpoint, missing patients in the surgical group were back in full patellar tendon loading activity (mean VAS during activity 9 ± 10). None of the two (2), at endpoint, missing patients in the sclerosing group were back in full tendon loading activity at short-term follow-up (mean VAS during activity 46 ± 12).
Discussion
The most important findings of the present study are that there were good clinical results, improved tendon structure and decreased local blood flow after both treatments, and decreased tendon thickness after US/CD-guided arthroscopic shaving.
We found a significantly decreased proximal patellar tendon thickness after the US/CD-guided arthroscopic shaving procedure, and this is, to the best of our knowledge, the first time this has been shown after treatment of patellar tendinopathy. The findings clearly show the potential in the soft tissue dorsal to the proximal patellar tendon, where interference with careful and precise US/ CD-guided surgical shaving, but not with US/CD-guided sclerosing injections, seems to have an impact on tendon thickness.
Treatment outside the dorsal tendon alone-combined with a relatively fast acceptance of full loading activity is in strong contrast to the worldwide used method using excision of macroscopically abnormal tendon tissue through a longitudinal tenotomy-combined with a long and careful rehabilitation period. It is interesting that this type of US/CD-guided treatment outside the dorsal tendon seems to produce markedly better clinical results and allow for a rather quick return to sports, than previously reported from intra-tendinous surgery [4] .
Over time, the blood flow was the first and quickest parameter to change (a decrease from high to low) in the and graphs with filled dots represent group B (arthroscopic shaving) at baseline, follow-up (15 months) and endpoint (46 months) surgical group. Furthermore, we found that the local blood flow (neovascularisation) had a strong correlation with patient satisfaction and pain during tendon loading activity, where high blood flow correlated with low patient satisfaction and high score for pain during activity. Tendon thickness was found to correlate with pain at rest, the larger the tendon thickness the higher score for pain at rest.
The US/CD-guided arthroscopic procedure rendered a quicker painless return to full activity and sports as well as a higher number of satisfied patients at short-term followup. At medium-term follow-up (&4 years), both treatments showed good results concerning pain reduction during activity and there were similar numbers of satisfied patients after treatment with sclerosing polidocanol injections. This might be due to that the US/CD-guided shaving procedure is more radical (the region with vessels and nerves is more traumatised) than the US/CD-guided sclerosing injection treatment, and interestingly, the correlation analysis showed that the arthroscopic shaving procedure was associated with a faster decrease in the local blood flow (neovascularisation).
These findings, being contradictory to those of former research, open for a new thinking and a need for further investigations into this direction. A recent study evaluating sclerosing polidocanol injection treatment in 101 patients with patellar tendinopathy showed that only a few patients were cured, and the majority of patients still reported substantial pain and showed reduced function after a 24-month follow-up [15] . In that study, the patients were treated with intervals of 4-6 weeks and the vessels entering from the ventral side of the tendon were injected. One can speculate whether the result really is comparable with sclerosing injections targeting the vessels and pathology on the dorsal side of the tendon, since there are no biopsy studies showing nerves in close relation to vessels on the ventral side of the proximal patellar tendon. It is also stated that about two-thirds of the patients with jumper's knee can be expected to have structural tendon changes with neovascularisation and that there was no relationship between changes in US characteristics and knee function after sclerosing treatment. The follow-up with US/CD examination was performed 12-15 months after the sclerosing treatment, which may be too early to detect changes. Our follow-up was done 3-5 years after treatment.
Treatment of patellar tendinopathy/jumper's knee has for many years puzzled clinicians, and the background to the pain has yet not been clarified in research. Vague knowledge about where the pain comes from, and varying clinical results with the different treatment methods in use, has raised many questions. Recent research on tissue specimens from patients with patellar tendinopathy has demonstrated that there are few nerves inside the tendon, but multiple nerves in close relation to blood vessels outside the dorsal side of the proximal patellar tendon [8] . Pilot studies using both US/CD-guided sclerosing polidocanol injections [21] and US-guided arthroscopic shaving [29] , targeting the region with high blood flow and nerves, have shown to significantly reduce tendon pain. There is vague knowledge about the patellar tendon US/CD findings after treatment with these new methods.
Lately, the sclerosing polidocanol injection treatment has been criticised based on data from a retrospective Dutch study [26] . The results from this prospective study clearly demonstrate beneficial effects without complications after treatment with sclerosing polidocanol injections. However, we believe that it needs to be emphasised that the original method description and indications should be followed (US/CD-guided injection of polidocanol 10 mg/ml, maximum 2 ml per treatment with at least 6-8 weeks in between treatments). Complications after injecting too large volumes, and injections given too often, do exist.
Treatment of patellar tendinopathy/jumper's knee with sclerosing injections requires multiple injections, in average 3 treatments, with at least 6-8 weeks in between. This makes it a time-consuming treatment method compared to the one-stage procedure US/CD-guided arthroscopic shaving. However, in contrast to the results at the 1-year follow-up, where the surgical method showed better results in all evaluated variables, both treatments seem to reach the same outcome in terms of improved tendon structure, decreased blood flow and self-reported pain during activity (VAS), in the 3-5-year perspective. The one and only remaining difference between the two treatment methods was the decrease in anteroposterior thickness of the tendon, which was shown only in the surgical group. In fact, the tendon thickness in the group treated with sclerosing injections increased at the 1-year follow-up, while 46 months after treatment the AP thickness seems to be back at baseline, i.e. the AP thickness of the tendon before treatment. In the surgical group, the tendon seems to show a greater improvement getting closer to a normal looking tendon-at endpoint of this study (Figs. 4, 5) .
It might be considered a weakness that no functional score, as the VISA-P, was used for the evaluation. However, the VISA-P score was not used at the beginning of the studies (baseline) from which the patients in this follow-up study are included. Instead, it was decided to focus on tendon pain during heavy loading of the tendon. It seemed appropriate to evaluate patellar tendon pain during their chosen specific recreational or sports activity together with satisfaction with the results of treatment and by adding a single question-''back in full patellar tendon loading activity-yes or no?'', when evaluating the clinical outcome in this study. Anyhow, since most other studies on sports-related injuries have used the VISA-P score system [11] and SF-36 [25] , it would have been good to be able to compare the results of the treatments to the results in other studies. However, the primary outcome in this study concerns the US/CD findings in the tendon (after treatment with US/CD-guided arthroscopic shaving and sclerosing injections) and correlation between pain during activity and at rest, satisfaction with treatment and US/CD findings, we found VAS to be an appropriate tool in the correlation analysis. We are aware of the relatively small groups, but when calculating the correlation, we used all the data at all times which gave us a rather large material to minimise the risk of a type II error in this follow-up study. Of course, there is a need for larger and long-term studies to evaluate the tendon changes, blood flow and correlation with pain during activity and results of treatment, especially since the results in this study are somewhat contradictory to all former studies in this area [17] .
It is important, though, for comparison in the future, that a score like the modified Ö hberg score is used to describe the US/CD findings in the chronic painful patellar tendon. Another problem when comparing different studies concerning treatment of patellar tendinopathy is that the widely used definition of patellar tendinopathy/jumper's knee, a solely clinical definition, is too blunt [5, 20] . Today, it is difficult to compare the patient material and results of treatment accurately in different studies since US/CD findings most often are not specified (described thoroughly) or not reported at all. The authors of this article believe that the modified Ö hberg score is a useful tool to specify and describe US/CD findings in tendinopathies. It would be helpful though, if further studies concerning a reproducible and reliable scoring system for US/CD findings in patellar tendinopathy were performed. Such scoring system, correlated to VISA-P and VAS for pain during activity, should lead us further in evaluating and comparing all the different treatment methods for chronic painful tendinotic proximal patellar tendinopathy in research in the future.
Conclusion
In conclusion, in this 3-5-year follow-up study, there was a remodelling and a sonographically more normal patellar tendon after successful treatment with US/CD-guided arthroscopic shaving. After treatment with sclerosing injections and arthroscopic shaving of jumper's knee, there was a correlation between low score for pain during activity, high patient satisfaction and low local blood flow. Both treatment methods rendered good and equal clinical results at 46 months, but US/CD-guided arthroscopic shaving showed a significantly faster return to sport activity.
